Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.

McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD.

Osteoporos Int. 2013 Jan;24(1):227-35. doi: 10.1007/s00198-012-2052-4. Epub 2012 Jul 10.

2.

Mild acidosis enhances AMPA receptor-mediated intracellular zinc mobilization in cortical neurons.

Frazzini V, Rapposelli IG, Corona C, Rockabrand E, Canzoniero LM, Sensi SL.

Mol Med. 2007 Jul-Aug;13(7-8):356-61.

3.

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, Sullivan PG, Steffan JS, Sensi SL, Thompson LM.

Hum Mol Genet. 2007 Jan 1;16(1):61-77. Epub 2006 Nov 29.

4.

Oxidative stress and brain aging: is zinc the link?

Frazzini V, Rockabrand E, Mocchegiani E, Sensi SL.

Biogerontology. 2006 Oct-Dec;7(5-6):307-14. Review.

PMID:
17028932
5.

Acidosis enhances toxicity induced by kainate and zinc exposure in aged cultured astrocytes.

Sensi SL, Rockabrand E, Canzoniero LM.

Biogerontology. 2006 Oct-Dec;7(5-6):367-74.

PMID:
16964527
6.

SUMO modification of Huntingtin and Huntington's disease pathology.

Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, Illes K, Lukacsovich T, Zhu YZ, Cattaneo E, Pandolfi PP, Thompson LM, Marsh JL.

Science. 2004 Apr 2;304(5667):100-4.

Supplemental Content

Loading ...
Support Center